Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
about
Ovarian serous carcinoma: recent concepts on its origin and carcinogenesisData set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)Fertility sparing treatment in borderline ovarian tumoursImmunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 casesKRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinomaBRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options.Tubal origin of ovarian low-grade serous carcinoma.The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancerOvarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problemsA meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants.A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancerPrognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovaryPhase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumorRecent progress in the diagnosis and treatment of ovarian cancerPatterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.Risk factors for recurrence of ovarian borderline tumors.Low-grade serous neoplasms of the ovary with transformation to high-grade carcinomas: a report of 3 cases.The molecular pathology of ovarian serous borderline tumors.KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions.Laparoscopy in the treatment of ovarian tumours of low malignant potential.Fine needle aspiration cytology of cervical lymph node involvement by ovarian serous borderline tumor.Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany.PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.Successful management of evisceration occurred after exploratory laparotomy for bilateral ovarian micropapillary serous borderline tumors.Advanced stage micropapillary serous borderline ovarian tumor in a postmenopausal woman: a case report.Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.Characterization and comparison of precursors of ovarian and endometrial carcinoma: parts I and II.Clinical management of borderline ovarian tumors.Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments.Fertility preservation in women with borderline ovarian tumors- how does it impact disease outcome? A cohort study.Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
P2860
Q26822545-CCC4270C-3A88-415C-B528-DFDFC67C00C7Q26852127-B79206D5-1302-410A-967A-C3B93D009362Q28081482-9AFB8C28-CF0E-4200-BA28-B794D756A4D9Q33387074-698493E8-A873-4CA2-B852-1792C4A20CCFQ33590020-8CEA568E-8B23-4755-8CE0-1EDD33BDFEBCQ33610751-08481004-A066-400A-8558-DC441D4A38CAQ33893010-B3D41F6B-F1AA-4249-94DF-F7572E673CE7Q34162272-CC6158E9-BCD0-482F-B7A2-C5DFB16528B3Q34317865-EC6A7E4E-3F8B-4A65-ABD7-3FE1057D854EQ34383567-6357F219-C8C9-46E6-925D-338B3703B11CQ34984679-8D62DF0F-11BB-4EB4-8AB3-7C0DDFB88C7DQ34998994-FF2220EE-CBE3-406D-BB11-C865F9D65385Q35057291-9FC3BF1D-BD87-451B-BB73-E3BF087F0C13Q35207499-2C473C37-ACC3-47C9-A613-8473C10CC6C0Q35209365-13F6CB08-EB26-489C-8700-C4F41DA09915Q35461505-7BEBDBB8-AD9E-4862-9FE8-B26C4EABD4B4Q35584451-29B9AF55-A0F4-4A46-A5AC-2AFEB01FA39AQ35628323-F8C504FA-8783-4143-935E-98F9270638B1Q36545843-5A6BAF1C-EC38-4249-99EF-217967925562Q36581350-47DA390D-0D62-473F-A10E-BAFFB3BF27FCQ36622857-DBDF9B2F-5CDF-4159-B681-A46D24E888ECQ36830657-9E21003A-F79C-479B-B7C7-20EBCAE9BD24Q36830662-F71BD18E-23F3-4AC1-AA3A-01431F04FDE6Q36847489-B39514A2-10C9-4E1F-A784-FFD2CD3452CFQ36855249-4B8FE0E7-C458-4D2A-AB86-3F2131497E89Q36939085-75414564-D79A-4E89-AC16-3AECC17ECEFAQ36996534-2816C011-1959-4F41-B5D6-5E3B6C8C82C4Q37161021-8D1A2CEC-DB8D-44D4-9A57-62E00118DC21Q37225708-66735461-F960-4DD4-BF57-6C1477118462Q37329264-50F88C02-D8BE-427D-A085-735650CDE4E9Q37376449-BA599CF3-EBC4-4185-821C-6CC05FA8C1BEQ37560515-93ED45D6-E6A8-48B9-9104-2DFF10C498C7Q37611303-6BAAA802-3623-4FE0-9E44-4524FAF0DFFBQ37632101-7EC17B27-4F36-4A1B-B41C-50450B9136E0Q37756401-080B43FC-C901-4C4F-9430-65B2076A85EAQ37774358-33FBB715-8C9D-470B-AFD8-B5D2AD50B853Q38067435-B0F07350-08CB-42F1-A9F1-D285D1F78650Q38203062-DE602D6B-2A63-40C8-8752-70AEC5AD62D1Q38620963-042C44AC-4170-42F6-A885-147B126752AEQ38679731-74A808A8-8B06-4A45-8CEF-FA6850916114
P2860
Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Ovarian serous tumors of low m ...... term (> or =5-year) follow-up.
@en
Ovarian serous tumors of low malignant potential
@nl
type
label
Ovarian serous tumors of low m ...... term (> or =5-year) follow-up.
@en
Ovarian serous tumors of low malignant potential
@nl
prefLabel
Ovarian serous tumors of low m ...... term (> or =5-year) follow-up.
@en
Ovarian serous tumors of low malignant potential
@nl
P2093
P1476
Ovarian serous tumors of low m ...... term (> or =5-year) follow-up.
@en
P2093
Henry D Tazelaar
Jesse K McKenney
Michael R Hendrickson
Richard L Kempson
Teri A Longacre
P304
P356
10.1097/01.PAS.0000164030.82810.DB
P407
P577
2005-06-01T00:00:00Z